Compounds > maackiain
Page last updated: 2024-12-08

maackiain

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID363863
CHEMBL ID239047
CHEBI ID73029
SCHEMBL ID12810278

Synonyms (43)

Synonym
BRD-A95445494-001-03-7
nsc629152
6h-[1,6]benzofuro[3,2-c][1]benzopyran-3-ol,6a,12a-dihydro-, (6ar-cis)- (ca index name)
nsc-629152
6a,12a-dihydro-6h-[1,3]dioxolo[4',5':5,6][1]benzofuro[3,2-c]chromen-3-ol
{6h-[1,3]dioxolo[5,6]benzofuro[3,} {2-c][1]benzopyran-3-ol,6a,12a-dihydro-,} (6ar-cis)- (ca index name)
DIVK1C_006653
SPECTRUM5_000036
ACON1_001470
SPECTRUM_000238
BSPBIO_001901
NCGC00095514-01
KBIOGR_001936
KBIO2_000718
KBIO1_001597
KBIO3_001401
KBIO2_005854
KBIOSS_000718
KBIO2_003286
SPBIO_001929
SPECPLUS_000557
SPECTRUM3_000231
SPECTRUM2_001925
SPECTRUM4_001528
SPECTRUM201654
NCGC00095514-02
NCGC00095514-03
chebi:73029 ,
CHEMBL239047
3-hydroxy-8,9-methylenedioxypterocarpane
6a,12a-dihydro-6h-[1,3]dioxolo[5,6][1]benzofuro[3,2-c]chromen-3-ol
CCG-38492
FT-0689334
AKOS015909127
SCHEMBL12810278
cis-6a,12a-dihydro-6h-[1,3]dioxolo[4',5':5,6]benzofuro[3,2-c]chromen-3-ol
6a,12a-dihydro-6h-[1,3]dioxolo[4',5':5,6][1]benzofuro[3,2-c]chromen-3-ol #
HUKSJTUUSUGIDC-UHFFFAOYSA-N
6a,12a-dihydro-6h-(1,3)dioxolo(5,6)benzofuro(3,2-c)chromen-3-ol
Q27140245
5,7,11,19-tetraoxapentacyclo[10.8.0.02,10.04,8.013,18]icosa-2,4(8),9,13(18),14,16-hexaen-16-ol
FT-0777978
dl-aackiain

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"This study aims to characterize the pharmacokinetic (PK) profiles and identify important bioavailability barriers and pharmacological pathways of the key active components (KACs) of Antitumor B (ATB), a chemopreventive agent."( Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
Bui, D; Duan, S; Hu, M; Singh, R; Wei, B; Wong, SJ; Yang, P; Yin, T; You, M, 2021)		0.62

Bioavailability

ExcerptReferenceRelevance
"This study aims to characterize the pharmacokinetic (PK) profiles and identify important bioavailability barriers and pharmacological pathways of the key active components (KACs) of Antitumor B (ATB), a chemopreventive agent."( Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
Bui, D; Duan, S; Hu, M; Singh, R; Wei, B; Wong, SJ; Yang, P; Yin, T; You, M, 2021)		0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
pterocarpansMembers of the class of benzofurochromene with a 6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromene skeleton and its substituted derivatives. They generally bear structural resemblance to isoflavanoids that possess antibiotic activity and are produced by plant tissues in response to infection. They are the 3,4-dihydroderivatives of coumestans.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
(-)-maackiain biosynthesis016
superpathway of pterocarpan biosynthesis (via formononetin)031
superpathway of formononetin derivative biosynthesis031
(+)-pisatin biosynthesis011
maackiain conjugates interconversion015

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1815095Antiinflammatory activity against human SCC-9 cells assessed as inhibition of LPS-induced PGE2 production at 10 ug/ml preincubated for 30 mins followed by stimulation with LPS and measured after 12 hrs by LC-MS/MS analysis2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815108Cmax in C57BL/6 mouse at 500 mg/kg, po2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815106Oral bioavailability in C57BL/6 mouse at 4000 mg/kg2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815104Clearance in C57BL/6 mouse at 500 mg/kg, iv administered as Antitumor B2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815094Antiproliferative activity against human SCC-9 cells assessed as cell viability measured after 72 hrs by MTT assay2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815122Cmax in C57BL/6 mouse at 500 mg/kg, ip qd measured after 7 days2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID378967Cytotoxicity against african green monkey Vero cells2006Journal of natural products, Jan, Volume: 69, Issue:1
Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID1815128Half life in C57BL/6 mouse at 500 mg/kg, ip qd measured after 7 days2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815116AUC (0 to infinity) in C57BL/6 mouse at 4000 mg/kg, po2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815114Cmax in C57BL/6 mouse at 4000 mg/kg, po2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815124AUC (0 to 24 hrs) in C57BL/6 mouse at 500 mg/kg, ip qd measured after 7 days2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815102AUC (0 to infinity) in C57BL/6 mouse at 500 mg/kg, iv administered as Antitumor B2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815118MRT (0 to 24 hrs) in C57BL/6 mouse at 4000 mg/kg, po2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815099Half life in C57BL/6 mouse at 500 mg/kg, iv administered as Antitumor B2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815130MRT (0 to 24 hrs) in C57BL/6 mouse at 500 mg/kg, ip qd measured after 7 days2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID378965Antileishmanial activity against Leishmania donovani MHOM/SD/62/IS-CL2D axenic amastigotes after 3 days2006Journal of natural products, Jan, Volume: 69, Issue:1
Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID1815113Tmax in C57BL/6 mouse at 4000 mg/kg, po2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID378968Cytotoxicity against human PC3 cells2006Journal of natural products, Jan, Volume: 69, Issue:1
Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID1815115AUC (0 to 24 hrs) in C57BL/6 mouse at 4000 mg/kg, po2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815100Cmax in C57BL/6 mouse at 500 mg/kg, iv administered as Antitumor B2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815107Tmax in C57BL/6 mouse at 500 mg/kg, po2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815121Cmax in C57BL/6 mouse at 500 mg/kg, ip qd measured after 1 day2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815103Volume of distribution in C57BL/6 mouse at 500 mg/kg, iv administered as Antitumor B2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815126AUC (0 to infinity) in C57BL/6 mouse at 500 mg/kg, ip qd measured after 7 days2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815093Antiproliferative activity against human CAL-27 cells assessed as cell viability measured after 72 hrs by MTT assay2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815112MRT (0 to 24 hrs) in C57BL/6 mouse at 500 mg/kg, po2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815101AUC (0 to 24 hrs) in C57BL/6 mouse at 500 mg/kg, iv administered as Antitumor B2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815109AUC (0 to 24 hrs) in C57BL/6 mouse at 500 mg/kg, po2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815105MRT (0 to 24 hrs) in C57BL/6 mouse at 500 mg/kg, iv administered as Antitumor B2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815119Tmax in C57BL/6 mouse at 500 mg/kg, ip qd measured after 1 day2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815129MRT (0 to 24 hrs) in C57BL/6 mouse at 500 mg/kg, ip qd measured after 1 day2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815098Stability in mouse blood assessed as compound remaining measured at - 80 degC for 4 months2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815120Tmax in C57BL/6 mouse at 500 mg/kg, ip qd measured after 7 days2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID378966Antitrypanosomal activity against Trypanosoma brucei brucei MITat 1.2 variant 221 after 72 hrs2006Journal of natural products, Jan, Volume: 69, Issue:1
Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID1815117Half life in C57BL/6 mouse at 4000 mg/kg, po2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815097Stability in mouse blood assessed as compound remaining measured at 20 degC for 8 hrs2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815096Stability in mouse blood assessed as compound recovery measured at 25 degC for 4 hrs2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1815123AUC (0 to 24 hrs) in C57BL/6 mouse at 500 mg/kg, ip qd measured after 1 day2021Journal of natural products, 09-24, Volume: 84, Issue:9
Pharmacokinetic Characterization and Bioavailability Barrier for the Key Active Components of Botanical Drug Antitumor B (ATB) in Mice for Chemoprevention of Oral Cancer.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.40 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.3110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		2.0310aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
suramin
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.		2.0310naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
oleanolic acid
[no description available]		2.0310hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.0310furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
dictamnine
dictamnine: furanoquinoline alkaloid; crosslinks DNA in presence of ultraviolet light		2.3110alkaloid antibiotic;
organic heterotricyclic compound;
organonitrogen heterocyclic compound;
oxacycle
matrine
[no description available]		2.3110alkaloid
fraxinellone
fraxinellone: structure given in first source; RN given for (3R-cis)-isomer		2.31102-benzofurans
7,4'-Di-O-methyldaidzein
[no description available]		2.0310methoxyisoflavone
isoliquiritigenin
[no description available]		2.0310chalconesantineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist
biochanin a
[no description available]		2.03104'-methoxyisoflavones;
7-hydroxyisoflavones		antineoplastic agent;
EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
formononetin
[no description available]		2.03104'-methoxyisoflavones;
7-hydroxyisoflavones		phytoestrogen;
plant metabolite
apigenin
Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.		2.0310trihydroxyflavoneantineoplastic agent;
metabolite
7,3'-dihydroxy-4'-methoxyisoflavone
7,3'-dihydroxy-4'-methoxyisoflavone: isolated from Astragali radix; structure in first source. calycosin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone which is substituted by an additional hydroxy group at the 3' position and a methoxy group at the 4' position.		2.03104'-methoxyisoflavones;
7-hydroxyisoflavones		antioxidant;
metabolite
genistein
[no description available]		2.03107-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
daidzein
[no description available]		2.03107-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
prunetin
prunetin: reduces herpes virus-1 plaque formation. prunetin : A hydroxyisoflavone that is genistein in which the hydroxy group at position 7 is replaced by a methoxy group.		2.03107-methoxyisoflavones;
hydroxyisoflavone		anti-inflammatory agent;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor;
metabolite
3',4',7-trihydroxyisoflavone
3',4',7-trihydroxyisoflavone: from Streptomyces sp OH-1049; structure given in first source. 3',4',7-trihydroxyisoflavone : A 7-hydroxyisoflavone that is daidzein substituted by a hydroxy group at position 3'.		2.03107-hydroxyisoflavonesantineoplastic agent;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor;
metabolite
7-hydroxyisoflavone
7-hydroxyisoflavone: effective against, Enterovirus 71; structure in first source. 7-hydroxyisoflavone : The simplest member of the class of 7-hydroxyisoflavones that is isoflavone with a hydroxy substituent at position 7.		2.03107-hydroxyisoflavonesEC 1.14.14.14 (aromatase) inhibitor;
metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Cancer of Mouth
[description not available]		02.3110
Mouth Neoplasms
Tumors or cancer of the MOUTH.		02.3110